NASDAQ NMS - GLOBAL MARKET · CELC
-1.05% · -$0.9400 · Vol 1.5M
Celcuity Inc

Celcuity Inc

Biotechnology
$88.55

Veridion Score

Loading
Score loading…
Veridion Score History · 90D

Composite trend over time

LOADING HISTORY…
REFRESHES DAILY
AI Analysis
Sovereign

Why is CELC moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Celcuity Inc
SERVICES-MEDICAL LABORATORIES
Founded
Listed
2017
Employees
155
HQ
US

Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.

Key statistics

Real vendor fields plus Veridion-computed history. Missing fields stay blank.

Open
$89.46
Day high
$91.00
Day low
$87.00
Previous close
$89.49
52W high
$90.45
-2.11% from high
52W low
$87.65
32% of range
Market cap
$4.4B
P/E
EPS
Dividend yield
Beta
Shares out
48.8M
Float
Volume
1.5M
Avg volume
VWAP
$88.84
Next earnings
Price history computed in-house
1W
+0.35%
1M
+0.35%
3M
+0.35%
1Y
+0.35%
YTD
+0.35%
SMA 50 $88.72 · below
SMA 200 $88.72 · below
52W position 32%
Veridion warehouse edge

Warehouse intelligence for CELC.

Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Loading quarterly statements…
SEC Form 4 ledger

CELC insider activity

Celcuity Inc

Score
Coverage building
Pressure
Net selling
Filings
36
Buys / sells
14 / 22
Net value
-$4.0M
Insiders
7
Named filers
LG
Laing Lance G.
Insider
Leadership
BE
Buller Richard E
Insider
Leadership
DD
Dalvey David
Insider
Leadership
Cluster

2 insiders bought in the last 90 days

Net pressure

Net selling: -$4.0M across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Filing dateTrade dateInsiderTitleTypePriceQtyOwnedValueReceipt
2026-06-042026-06-02Laing Lance G.Insiderbuy$9.891,0001,251,000$10KSEC Form 4
2026-05-062026-05-04Buller Richard EInsidersell$143.243656,760$52KSEC Form 4
2026-05-062026-05-04Buller Richard EInsidersell$142.042,8257,125$401KSEC Form 4
2026-05-062026-05-04Buller Richard EInsidersell$141.032,3019,950$325KSEC Form 4
2026-05-062026-05-04Buller Richard EInsidersell$139.581,67012,251$233KSEC Form 4
Full Form 4 history requires Sovereign

Showing 5 recent rows. Sovereign unlocks 31 additional rows, full sorting, and the named-filer history.

Upgrade to Sovereign · $25/mo
Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology
Congress · 90D
Loading PTR filings…
Federal contracts

CELC contract awards, year to date.

Public federal awards linked to this ticker.

Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for CELC in this window.
Lobbying spend

CELC lobbying filings, year to date.

Registered lobbying filings matched to Celcuity Inc.

Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for CELC in this window.
Latest news · CELC
Refresh interval: 5 minutes · Source: Market news insights
Loading articles…
Analyst ratings
Sovereign unlock shows live analyst consensus for CELC.
Options
Sovereign unlock shows live options positioning for CELC.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.